Medication info
Empagliflozin/Metformin Extended Release Tablets 10/1000 mg (Empagliflozin, Metformin)

Empagliflozin/Metformin Extended Release Tablets 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Light pink, bilaterally convex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501724 · Approved 2025.07.09 · Insurance code 642507910

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken once daily in the evening with a meal. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial dose when taking this drug is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this drug from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Poor blood sugar control in adults with type 2 diabetes
  • cardiovascular diseases
View approved original text

This medicine helps improve blood sugar control in adults with type 2 diabetes by combining the effects of empagliflozin and metformin. It is used as an adjunct to diet and exercise and is particularly effective for patients whose blood sugar is not adequately controlled. Additionally, caution is advised regarding cardiovascular events in diabetic patients with cardiovascular diseases; therefore, it is important to follow a healthcare professional's guidance. This medicine is used to enhance blood sugar control and assist in diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken once daily in the evening with a meal. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse effects associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. This drug may not dissolve completely and may be excreted in the stool. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial dose when taking this drug is a total daily dose of empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching to this drug from combination therapy with empagliflozin and metformin should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this drug may be used with metformin hydrochloride dose adjustment as follows, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medicine is used for treating diabetes, with two components working together to control blood sugar. Patients with impaired renal function, certain heart diseases, or liver dysfunction should not use this medicine. Moreover, the use of this medicine should be temporarily discontinued in cases of acute infections, dehydration, or before and after surgery, and it should only be resumed once kidney function has returned to normal. This medicine can cause a rare side effect called severe lactic acidosis; if symptoms such as muscle pain, difficulty breathing, or weakness occur, medical personnel should be notified immediately. There is a risk of hypoglycemia when used with insulin or other hypoglycemic agents, so blood sugar levels should be monitored frequently, and dosage adjustments may be necessary. This medicine can increase the risk of urinary tract infections and genital infections, so prompt treatment should be sought if related symptoms appear. Elderly patients or those at risk of decreased fluid volume should be cautious of dehydration and low blood pressure, and should undergo regular kidney function tests. It is advisable that pregnant women, women who may become pregnant, and nursing mothers do not use this medicine. This medicine should be swallowed whole and not crushed or chewed; it is normal for the medication's coating to pass in the stool. Alcohol consumption should be avoided during treatment, and administration should be halted before and after certain imaging tests. During treatment with this medicine, blood sugar control should be continuously monitored, and any unusual symptoms should prompt immediate consultation with a healthcare professional.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
Show 170 more
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbances
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • reduced and deficient vitamin B12
  • ketoacidosis
  • decreased fluid volume
  • perineal necrosis
  • urinary tract infection
  • urosepsis
  • pyelonephritis
  • headache
  • dizziness
  • cerebral infarction
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorders
  • oral discomfort
  • salivary gland pain
  • sensory disturbance
  • orthostatic dizziness
  • amnesia
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • drowsiness
  • CNS-origin vertigo
  • weakness
  • peripheral edema
  • facial edema
  • peripheral swelling
  • chills
  • unusual sensations
  • swelling
  • pain
  • pain at the puncture site
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral stones
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • hypercontraction bladder
  • renal masses
  • urine retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • striae
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • dermal cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • macular retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • skin lacerations
  • bruising
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • iliotibial band syndrome
  • open eye injury
  • pelvic fractures
  • road traffic accidents
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid masses
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine may be sensitive to air or moisture; it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1°C and 30°C. This helps maintain the effectiveness of the medication for a longer time.

Appearance and packaging

Appearance

Light pink, bilaterally convex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.